Phathom Pharmaceuticals prices $130M public offering of common stock and pre-funded warrants

Phathom Pharmaceuticals, Inc.

6,875,000 shares of common stock at $16.00/share and pre-funded warrants for 1,250,078 shares at $15.999/warrant.
Gross proceeds approximately $130M; underwriters have 30-day option for additional 1,218,761 shares.
Net proceeds for general corporate purposes, including working capital and R&D.
Offering expected to close on/about January 9, 2026; Guggenheim Securities and Cantor are joint bookrunners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.